TG Therapeutics, Inc.(TGTX)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
$55.07
- 52-Week Range
- $25.28 – $57.38
- YTD
- +88.10%
- IV Rank (30D)
- 44.81
- Straddle Price
- $6.42
- P/C Vol Ratio
- 0.14
- Market Cap
- $8.1B
Fair Value
-3.7% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.49% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 9.99% (VRP-adj) |
| WACC | 9.57% |
| Volatility Risk Premium | +19.6pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | 79.2% |
| Book / Price | 6.8% |
| Gross Margin (TTM) | 83.1% |
| FCF Margin (TTM) | -2.0% |
| Debt / Equity | 1.28 |
| Quality Score | 3/6 — normal (10y DCF) |
| SMA 50 | $39.74 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $43.14 |
| Bollinger Width / SMA20 | 114.3% (drives anchor stability) |
| Net Debt | $0.3B |
| Market Cap | $9B |
Peers used for multiples: ALKS, BTSG, CORT, CPRX, KRYS, MOH, PTCT, PTGX
Blended Fair Value
$53.23
Current Price
$55.30
Deviation
-3.7%
Forward-Return Rank
SHORT
gates ✓
?
| Horizon | Expected α | z Pred | Blended z | Rank % | Active? |
|---|---|---|---|---|---|
| 21d | -1.8% | +0.88 | -0.44 | 89.5% | — |
| 42d | -3.3% | +0.90 | -0.44 | 89.5% | — |
| 63d | -3.5% | +0.71 | -0.44 | 89.5% | — |
Expected α = forward-return point estimate vs SPY (e.g., +7.5% means the predictor expects this stock to outperform SPY by 7.5% over that horizon).
For SHORT direction the model uses a different ranking metric (conviction-weighted deviation, not the LGBM prediction); Expected α is shown for reference.
⚠ flags rows where Expected α disagrees with the FV direction — two independent signals are in conflict; conviction is low even if rank looks extreme.
Forward-Return Rank. A proprietary ensemble of a machine-learning forward-return model and a conviction-weighted fundamental score, ranked cross-sectionally each day across the S&P 500 (and broader universes on the screener). Each stock is scored at three horizons (21/42/63 trading days). "Active" = top/bottom 5% AND all risk filters pass. Backtested mean alpha vs SPY on active picks: 21d LONG +13.4%, 63d +34.9% (S&P 500, walk-forward). Past performance is not indicative of future results.
Value vs momentum conflict ⚠. The "FV direction" (long/short) comes from the fundamentals-based engine — price vs intrinsic value. The "Expected α" comes from a separate machine-learning predictor trained on ~12 features (sector, options-implied move, beta, institutional flow, etc.). Sometimes the two disagree: a stock is overvalued by fundamentals but the predictor expects it to keep outperforming (sector or momentum tailwinds). When all 3 horizons disagree, treat the direction signal as low-conviction — neither model is strongly recommending a position.
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $149.48 | 15% | median 47.4× · 6 peers |
| Peer EV/EBITDA | $26.44 | 15% | median 27.8× · 5 peers |
| Peer P/B | $23.76 | 3% | median 6.6× · 7 peers |
| Peer P/S | $34.30 | 10% | median 7.2× · 8 peers |
| Market Anchor (SMA50) | $39.74 | 57% | stability 85% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-06-22 · updated 2026-06-22 19:19:32.849000
Info
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $8.1B
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to…
Chart
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +4.62% | 13 |
| Feb | +6.89% | 13 |
| Mar | +10.98% | 13 |
| Apr | +2.23% | 13 |
| May | -2.09% | 14 |
| Jun | +7.29% | 14 |
| Jul | -0.31% | 13 |
| Aug | +0.33% | 13 |
| Sep | -3.28% | 13 |
| Oct | -6.34% | 13 |
| Nov | +13.19% | 13 |
| Dec | +9.32% | 13 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $43.95
SMA 50: $40.15
SMA 200: $33.77
Current: $55.40
EMA 12: $48.58
EMA 26: $44.65
MACD: 3.9304 | Signal: 1.2067
BULLISH
ADX (14): 44.80
STRONG TREND
+DI: 48.74
−DI: 6.85
Momentum Oscillators
RSI (14): 85.22
OVERBOUGHT
Stoch %K: 90.51
Stoch %D: 92.51
Williams %R: -9.48
Volume & Volatility
BB Upper: $55.67
BB Lower: $32.22
NEUTRAL
OBV: 82,682,963
Vol SMA 20: 2,469,067
Vol ROC: 24.02%
ATR: $2.40
True Range: $4.16
HV 20: 49.5%
HV 30: 47.4%
HV 60: 52.5%
Data Summary
Data Points: 500
Last Updated: 2026-06-22T19:20:25.453000
Date Range: 2024-06-21T00:00:00 – 2026-06-18T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
TG Therapeutics stock is on an absolute rampage, climbing 79% in roughly the first six months of the year, as the biotech takes on Roche. The post TG Therapeutics Stock Is On A Hot Streak: Why It's Up 79% And Climbing appeared first on Investor's Business Daily .
TG Therapeutics is Wednesday's IBD Stock Of The Day. Shares broke out as the relative strength line hit a new high. The post Why This IBD Stock Of The Day, A Roche Rival, Just Broke Out To A Five-Year High appeared first on Investor's Business Daily .
TG Therapeutics stock popped Wednesday after the biotech company said an under-the-skin shot of Briumvi appeared as safe as the IV. The post TG Therapeutics Flashes An Early Buy Signal — What Drove The Bullish Jump appeared first on Investor's Business Daily .
Earnings History
6 of 8 under expected move
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-08-06 | Pre-Market | 18.22% | 15.54% | 0.85x | Within |
| 2024-11-04 | Pre-Market | 17.88% | 9.85% | 0.55x | Within |
| 2025-03-03 | Pre-Market | 13.13% | 14.42% | 1.10x | Exceeded |
| 2025-05-05 | Pre-Market | 14.94% | 12.94% | 0.87x | Within |
| 2025-08-04 | Pre-Market | 14.37% | 16.44% | 1.14x | Exceeded |
| 2025-11-03 | Pre-Market | 16.17% | 2.96% | 0.18x | Within |
| 2026-02-26 | After-Close | 10.11% | 2.39% | 0.24x | Within |
| 2026-05-06 | After-Close | 8.71% | 3.79% | 0.44x | Within |
Options Activity
- IV Rank (30D)
- 44.81
- IV Rank (7D)
- 44.81
- Avg IV
- 72.2%
- Straddle (30D)
- $6.42
- Straddle (7D)
- $6.42
- P/C Volume
- 0.14
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 0.61
- Correlation (SPY)
- 16.1%
- R²
- 0.03
- Ann. Volatility
- 47.3%
- SPY Volatility
- 12.4%
Low volatility - stock moves less than market
Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
? 13F Guide
Diluted shares outstanding: 161,258,113 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
15 filers$82.38M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $32.55M | 39.52% | 2026-03-31 |
| 2 | GROUP ONE TRADING LLC Custodian | $11.10M | 13.47% | 2026-03-31 |
| 3 | CITADEL ADVISORS LLC Custodian | $10.20M | 12.38% | 2026-03-31 |
| 4 | GOLDMAN SACHS GROUP INC Custodian | $7.97M | 9.68% | 2026-03-31 |
| 5 | SIMPLEX TRADING, LLC Custodian | $4.14M | 5.02% | 2026-03-31 |
| 6 | JANE STREET GROUP, LLC Custodian | $3.78M | 4.59% | 2026-03-31 |
| 7 | IMC-Chicago, LLC Custodian | $3.62M | 4.39% | 2026-03-31 |
| 8 | Twin Tree Management, LP | $1.90M | 2.31% | 2026-03-31 |
| 9 | Caption Management, LLC | $1.66M | 2.02% | 2026-03-31 |
| 10 | Walleye Trading LLC | $1.55M | 1.88% | 2026-03-31 |
| 11 | MILLENNIUM MANAGEMENT LLC Custodian | $1.27M | 1.54% | 2026-03-31 |
| 12 | CITIGROUP INC Custodian | $996.60K | 1.21% | 2026-03-31 |
| 13 | BALYASNY ASSET MANAGEMENT L.P. | $654.43K | 0.79% | 2026-03-31 |
| 14 | D. E. Shaw & Co., Inc. Custodian | $504.94K | 0.61% | 2026-03-31 |
| 15 | Walleye Capital LLC | $475.05K | 0.58% | 2026-03-31 |
13 filers$82.33M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | JANE STREET GROUP, LLC Custodian | $33.06M | 40.16% | 2026-03-31 |
| 2 | GOLDMAN SACHS GROUP INC Custodian | $18.27M | 22.19% | 2026-03-31 |
| 3 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $15.54M | 18.88% | 2026-03-31 |
| 4 | CITADEL ADVISORS LLC Custodian | $7.11M | 8.63% | 2026-03-31 |
| 5 | GROUP ONE TRADING LLC Custodian | $2.99M | 3.64% | 2026-03-31 |
| 6 | SIMPLEX TRADING, LLC Custodian | $1.02M | 1.24% | 2026-03-31 |
| 7 | CITIGROUP INC Custodian | $996.60K | 1.21% | 2026-03-31 |
| 8 | Caption Management, LLC | $996.60K | 1.21% | 2026-03-31 |
| 9 | Walleye Capital LLC | $886.97K | 1.08% | 2026-03-31 |
| 10 | IMC-Chicago, LLC Custodian | $757.42K | 0.92% | 2026-03-31 |
| 11 | Walleye Trading LLC | $425.22K | 0.52% | 2026-03-31 |
| 12 | UBS Group AG Custodian | $209.29K | 0.25% | 2026-03-31 |
| 13 | Twin Tree Management, LP | $59.80K | 0.07% | 2026-03-31 |
Insider Activity
Latest: 2026-06-15
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-15 | Sagar Lonial | Director | Grant (A) | +8,325 RSU | — | EDGAR | |
| 2026-06-15 | Yann Echelard | Director | Grant (A) | +8,325 RSU | — | EDGAR | |
| 2026-06-15 | DANIEL HUME | Director | Grant (A) | +8,325 RSU | — | EDGAR | |
| 2026-06-15 | Laurence N Charney | Director | Grant (A) | +8,325 RSU | — | EDGAR | |
| 2026-06-15 | Kenneth Hoberman | Director | Grant (A) | +8,325 RSU | — | EDGAR | |
| 2026-01-29 | Laurence N Charney | Director | Gift (G) | −43,197 | — | EDGAR | |
| 2026-01-09 | MICHAEL S WEISS | CEO | Award (A) | +622,000 | — | EDGAR | |
| 2026-01-09 | Sean A Power | CFO | Award (A) | +90,000 | — | EDGAR | |
| 2025-11-25 | Yann Echelard | Director | Sell (S) | −5,000 | $32.57 | -$162.8K | EDGAR |
| 2025-11-07 | MICHAEL S WEISS | CEO | Gift (G) | −4,668,843 | — | EDGAR | |
| 2025-09-12 | Sagar Lonial | Director | Sell (S) | −20,852 | $32.24 | -$672.3K | EDGAR |
| 2025-06-16 | Kenneth Hoberman | Director | Award (A) | +14,718 | — | EDGAR | |
| 2025-06-16 | Laurence N Charney | Director | Award (A) | +21,408 | — | EDGAR | |
| 2025-06-16 | Yann Echelard | Director | Mixed | +4,718 | $36.94 | -$369.4K | EDGAR |
| 2025-06-16 | DANIEL HUME | Director | Award (A) | +14,718 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
12 insiders · @ $55.40
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | MICHAEL S WEISS | CEO | 24,212,300 | $1.34B | -$3.35M | 23 | 2026-01-09 |
| 2 | Rajeev M. Shah | 10%+ Owner | 12,629,868 | $699.63M | -$12.28M | 1 | 2020-09-11 |
| 3 | LFB Biotechnologies S.A.S.U. | 10%+ Owner | 7,614,855 | $421.82M | $750.0K | 1 | 2015-05-11 |
| 4 | Sean A Power | CFO | 798,111 | $44.21M | -$10.50M | 27 | 2026-01-09 |
| 5 | Kenneth Hoberman | Director | 279,653 | $15.49M | $0 | 12 | 2026-06-15 |
| 6 | Yann Echelard | Director | 223,816 | $12.40M | -$2.13M | 17 | 2026-06-15 |
| 7 | Laurence N Charney | Director | 192,887 | $10.68M | -$1.85M | 20 | 2026-06-15 |
| 8 | DANIEL HUME | Director | 192,748 | $10.68M | $0 | 12 | 2026-06-15 |
| 9 | MARK SCHOENEBAUM | Director | 125,949 | $6.98M | $0 | 5 | 2018-06-28 |
| 10 | WILLIAM JAMES KENNEDY | Director | 109,633 | $6.07M | -$856.9K | 10 | 2020-06-24 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Notice of Proposed Sale (Form 144)
Latest: 2025-11-24
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.
Source & freshness: Parsed directly from EDGAR primary-doc XML. Daily refresh; new filings typically appear here the morning after they hit EDGAR.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2025-11-24 | Echelard Yann | Director | 5,000 | $162.8K | 2025-11-24 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-09-11 | Lonial Sagar | Director | 20,852 | $672.2K | 2025-09-11 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-06-13 | Echelard Yann | Director | 10,000 | $369.3K | 2025-06-13 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-01-06 | Power Sean A | Officer | 10,021 | $285.9K | 2025-01-06 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2025-01-03 | Power Sean A | Officer | 11,337 | $343.4K | 2025-01-03 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2024-11-12 144/A | Charney Laurence N | Director | 25,000 | $754.9K | 2024-11-11 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2024-11-12 | Charney Laurence N | Director | 25,000 | $754.9K | 2024-11-11 | TG THERAPEUTICS, INC. | — | EDGAR |
| 2024-11-12 | Lonial Sagar | Director | 5,000 | $152.2K | 2024-11-11 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2024-11-05 | Echelard Yann | Director | 20,000 | $489.5K | 2024-11-05 | Fidelity Brokerage Services LLC | — | EDGAR |
| 2024-06-20 | Lonial Sagar | Director | 7,430 | $125.3K | 2024-06-20 | Fidelity Brokerage Services LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/E Ratio | 19.2 |
| P/B Ratio | 14.0 |
| P/S Ratio | 11.6 |
| EV/EBITDA | 56.5 |
| TTM Revenue | $0.7B |
| TTM Net Income | $0.5B |
| TTM EPS | $2.87 |
| ROE | 79.2% |
| Debt/Equity | 1.28 |